| Autor: |
Jefremow A; Department of Medicine 1, University Erlangen-Nürnberg, 91054 Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany., Neurath MF; Department of Medicine 1, University Erlangen-Nürnberg, 91054 Erlangen, Germany.; Deutsches Zentrum Immuntherapie (DZI), 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany. |
| Abstrakt: |
Biologicals have dominated the therapeutic scenery in inflammatory bowel diseases (IBDs), namely ulcerative colitis (UC) and Crohn's disease (CD), for the past 20 years. The development of tofacitinib was the starting point for an era of small molecules after the era of biologicals. These new agents may challenge the use of biological agents in the future. They share properties that appeal to both patients and physicians. Low production costs, a lack of immunogenicity, and ease of use are only some of their benefits. On the other hand, patients and their physicians must manage the potential side effects of small molecules such as JAK inhibitors or S1P1R modulators. Here, we present agents that have already entered the clinical routine and those that are still being investigated in clinical trials. |
